Patent ID: 9459264
Filing Date: 2016-10-04
CPC Classification: A61K,A61P,G01N

Claim Text:
1. A method for determining whether a subject is at risk to develop one or more complications of cardiovascular disease (CVD), wherein the one or more complications are death, myocardial infarction, acute myocardial infarction, angina pectoris, transient ischemic attack, or stroke, said method comprising: (a) determining in a sample from said subject one or more lipid-lipid ratio(s), wherein (an) increased lipid-lipid ratio(s) in said sample, when compared to a control sample, is (are) indicative of said subject having an increased risk of developing the one or more complications of CVD, wherein the one or more lipid-lipid ratio(s) whose increase(s) is (are) compared to the control is (are) selected from: Cer(d18:1/16:0)/LPC 16:0, Cer(d18:1/16:0)/Total LPC, Cer(d18:1/20:0)/LPC 18:2 and Cer(d18:1/22:0)/LPC 18:2; and/or (b) determining in a sample from said subject one or more lipid-clinical concentration ratio(s), wherein (an) increased or decreased lipid-clinical concentration ratio(s) in said sample, when compared to a control sample, is (are) indicative of said subject having an increased risk of developing the one or more complications of CVD, wherein the one or more lipid-clinical concentration ratio(s) whose increase(s) is (are) compared to the control is (are) selected from: Cer(d18:1/16:0)/apolipoprotein B, Cer(d18:1/16:0)/HDL cholesterol, Cer(d18:1/16:0)/HDL cholesterol ester, Cer(d18:1/16:0)/HDL phospholipid, Cer(d18:1/16:0)/total cholesterol, Cer(d18:1/16:0)/Chol, Cer(d18:1/16:0)/cholesterol ester, Cer(d18:1/16:0)/free cholesterol, Cer(d18:1/16:0)/LDL phospholipid, Cer(d18:1/20:0)/apolipoprotein A-I, Cer(d18:1/20:0)/HDL phospholipid, Cer(d18:0/22:0)/apolipoprotein A-II, Cer(d18:0/22:0)/HDL cholesterol ester, Cer(d18:1/22:0)/apolipoprotein A-I, Cer(d18:1/22:0)/cholesterol ester, Cer(d18:1/22:0)/LDL cholesterol, Cer(d18:1/22:0)/total cholesterol, Cer(d18:0/24:1)/apolipoprotein A-II, Cer(d18:0/24:1)/HDL cholesterol ester, Cer(d18:1/24:1)/apolipoprotein A-II, Cer(d18:1/24:1)/cholesterol ester, Cer(d18:1/24:1)/LDL, Cer(d18:1/24:1)/LDL phospholipid, Total Cer/apolipoprotein A-I, Total Cer/apolipoprotein A-II, Total Cer/cholesterol ester, Total Cer/total and cholesterol; wherein the one or more lipid-clinical concentration ratio(s) whose decrease(s) is (are) compared to the control is (are) selected from: Cer(d18:1/18:0)/TG, Cer(d18:0/22:0)/TG, Cer(d18:1/22:0)/TG, Cer(d18:1/24:0)/Chol, Cer(d18:0/24:1)/TG, Cer(d18:1/26:0)/Chol and Cer(d18:1/26:0)/TG, and wherein said determining comprises determining at least two lipid-lipid concentration ratios or at least two lipid-clinical concentration ratios or a combination of at least one lipid-lipid concentration ratio and at least one lipid-clinical concentration ratio.